Evidence map›Paper›PMID 37056402›Full record

ArticleFrontiers in psychiatry2023

Deficits in odor discrimination versus odor identification in patients with schizophrenia and negative correlations with GABAergic and DNA methyltransferase mRNAs in lymphocytes.

Robert C Smith, Henry Sershen, Mary Youssef, Abel Lajtha, Hua Jin, Mumei Zhang, Anmei Chen, Alessandro Guidotti, John M Davis

Open access · goldAbstract read
In one paragraph

Article in Frontiers in psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Robert C SmithNathan Kline Institute for Psychiatric Research, Orangeburg, NY, United States.
Henry SershenNathan Kline Institute for Psychiatric Research, Orangeburg, NY, United States.
Mary YoussefNathan Kline Institute for Psychiatric Research, Orangeburg, NY, United States.
Abel LajthaNathan Kline Institute for Psychiatric Research, Orangeburg, NY, United States.
Hua JinDepartment of Psychiatry and VA San Diego Healthcare System, University of California San Diego, San Diego, CA, United States.
Mumei ZhangColumbia University Mailman School of Public Health, New York, NY, United States.
Anmei ChenColumbia University Mailman School of Public Health, New York, NY, United States.
Alessandro GuidottiDepartment of Psychiatry, Psychiatric Institute University of Illinois, Chicago, IL, United States.
John M DavisDepartment of Psychiatry, Psychiatric Institute University of Illinois, Chicago, IL, United States.
Nathan Kline Institute for Psychiatric Research · USColumbia University · USUniversity of Illinois Chicago · USVA San Diego Healthcare System · US

Funding

Epigenetic Markers For Development of SchizophreniaR01MH101043 · NIMH · UNIVERSITY OF ILLINOIS AT CHICAGO · PI GUIDOTTI, ALESSANDRO · 2013 to 2015
$595k
NIMH NIH HHS R01 MH101043
6 · The paper itself

Abstract

Introduction: People with schizophrenia have been reported to show deficits in tests of olfactory function. DNA methylation and GABAergic input have been implicated in biochemical processes controlling odor in animal studies, but this has not been investigated in human studies. Methods: In a study of measures of DNA methylation and GABAergic mRNAs in lymphocytes, we also measured odor identification and discrimination with the Sniffin' Sticks battery in 58 patients with chronic schizophrenia (CSZ) and 48 controls. mRNAs in lymphocytes were assessed by qPCR using TaqManTM probes. Cognition was assessed by the MATRICS battery (Measurement and Treatment Research to Improve Cognition in Schizophrenia) in CSZ and controls, and symptoms in CSZ were assessed by PANSS scale (Positive and Negative Symptom Scale). The relationships of odor deficits with mRNA, cognition, and symptoms were explored by correlation analysis. Variables which significantly differentiated CSZ from controls were explored by logistic regression. Results: Overall, CSZ showed significantly (P≤.001) lower scores on odor discrimination compared to controls, with a moderate effect size, but no difference in odor identification. Deficits in odor discrimination, which has not been standardly assessed in many prior studies, strongly differentiated CSZ from controls. In logistic regression analysis, odor discrimination, but not odor identification, was a significant variable predicting schizophrenia versus control class membership. This is the first study to report relationship between odor deficits and DNA methylation and GABAergic mRNAs in blood cells of human subjects. There were negative correlations of odor identification with DNA methylation enzymes mRNAs and significant negative correlations with odor discrimination and GABAergic mRNAs. Lower odor scores were significantly associated with lower cognitive scores on the MATRICS battery in CSZ but not control subjects. In CSZ, lower odor scores were significantly associated with negative symptom scores, while higher odor identification scores were associated with PANNS Excitement factor. Discussion: Odor discrimination was a more powerful variable than odor identification in discriminating CSZ from controls and should be used more regularly as an odor measure in studies of schizophrenia. The substantive meaning of the negative correlations of odor discrimination and GABAergic mRNA variables in peripheral lymphocytes of CSZ needs more investigation and comparison with results in neural tissue.

Indexed as

GABAergic mRNAMATRICS batteryodor discriminationolfactory deficitsschizophrenia

Identifiers

PMID37056402
PMCPMC10088370
OpenAlexW4361214274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.